free web stats

Law Offices of Thomas J. Lamb

Ozempic NAION Risk 200% Higher Than Some Other Diabetes Drugs

By

The semaglutide-containing drug Ozempic has been linked to non-arteritic anterior ischemic optic neuropathy (NAION). A 2026 medical journal article reported that the Ozempic NAION risk 200% higher than that of some other diabetes drugs, such as Invokana (canagliflozin), Jardiance (empagliflozin), and Farxiga (dapagliflozin), which are sodium-glucose cotransporter-2 (SGLT2) inhibitors, also referred to as SGLT2i drugs. Like Ozempic, the SGLT2 inhibitors Invokana, Jardiance, and Farxiga are used to treat Type 2 diabetes.

This article, “New-Onset Nonarteritic Anterior Ischemic Optic Neuropathy and Initiators of Semaglutide in US Veterans With Type 2 Diabetes”, published in February 2026 by the medical journal JAMA Ophthalmology, begins with a “Key Points” part that includes the following:

Question Is semaglutide associated with an increased risk of incidence of nonarteritic anterior ischemic optic neuropathy (NAION) compared with sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with type 2 diabetes?

Findings In this study, among a group of US veterans with type 2 diabetes, initiation of semaglutide was associated with a 2-fold higher risk of incident NAION compared with initiation of an SGLT2i,…

In addition to Ozempic, two other semaglutide-containing drugs are Wegovy and Rybelsus, so this new evidence about the Ozempic NAION risk applies to those drugs, also. We point out that Novo Nordisk is the pharmaceutical company responsible for Ozempic, Wegovy, and Rybelsus.

Ozempic NAION Risk: Earlier Posts

Here are some of the earlier posts relevant to this recently reported medical fact that the Ozempic NAION risk 200% higher than that of some other diabetes drugs:

The current drug labels for Ozempic, Wegovy, and Rybelsus do not warn about non-arteritic anterior ischemic optic neuropathy (NAION)as a possible eye-related side effect that can cause vision loss.

Given that situation, together with newly reported evidence of the Ozempic NAION risk 200% higher than that of some other diabetes drugs, we are handling drug injury lawsuits for patients who developed the NAION eye-related side effect associated with Ozempic, Wegovy, and Rybelsus.

Drug injury lawsuits involving Ozempic, Wegovy, and Rybelsus for patients diagnosed with NAION would be filed against Novo Nordisk for its failure to warn about NAION as a possible side effect.

If you have a possible Rybelsus, Wegovy, or Ozempic NAION case that you would like to have investigated for a drug injury lawsuit, you can submit an online Case Evaluation Form. If you prefer, send attorney Tom Lamb an email (TJL@LambLawOffice.com) or call him (910-256-2971)..

[Read the article in full at Drug Injury Watch]

Ozempic / Rybelsus / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

A Rybelsus Blood Clots DVT Case

By

We have been investigating Ozempic, Wegovy, and Rybelsus blood clots, deep vein thrombosis (DVT), and pulmonary embolism (PE) cases as possible drug injury lawsuits against the pharmaceutical company Novo Nordisk. Starting in or about 2021, Ozempic, Wegovy, and Rybelsus — the three Novo Nordisk semaglutide-containing drugs — have been associated with a significantly increased risk of blood clots. In this post, we point out a recent medical journal article that discusses a Rybelsus blood clots DVT case involving a teenage boy.

From the Abstract part of this medical journal article, “Deep Venous Thrombosis Within Two Weeks of Initiating Oral Semaglutide (Rybelsus): A Case Report”, we get some information about the Rybelsus blood clots DVT case:

We report the case of a 16-year-old male with mild conventional risk factors for thrombosis [overweight body mass index (BMI) and prolonged sedentary behavior] who developed acute left lower extremity deep venous thrombosis (DVT) within two weeks of initiating [Rybelsus (oral semaglutide)] for weight reduction without medical supervision. He presented with progressive leg pain and swelling, and duplex ultrasonography revealed thrombosis of the distal superficial femoral and popliteal veins….

This case suggests a possible association between [Rybelsus (oral semaglutide)] and venous thrombosis in an adolescent, highlighting the need for careful supervision during off-label use.

We have written previously about the Ozempic, Wegovy, and Rybelsus blood clots side effects of deep vein thrombosis (DVT) and pulmonary embolism (PE):

Semaglutide-Related Blood Clots Cases: Ozempic, Wegovy, and Rybelsus

Deep Vein Thrombosis When Using Wegovy, Rybelsus, or Ozempic

Wegovy / Rybelsus / Ozempic Deep Vein Thrombosis Side Effects

We can assist individuals with a Rybelsus blood clots DVT case if they submit an online Case Evaluation Form or call us at 910-256-2971.

[Read the article in full at Drug Injury Watch]

Ozempic / Rybelsus / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

Mounjaro and Ozempic NAION Vision Loss Lawsuits: Federal Court MDL No. 3163

By

As seen elsewhere on this Drug Injury Law website, we have been investigating Mounjaro and Ozempic NAION vision loss lawsuits seeking legal compensation for the person suffering from this serious eye side effect injury:

As indicated on those two webpages, Mounjaro NAION vision loss lawsuits would be filed against Eli Lilly, and Ozempic NAION vision loss lawsuits would be filed against Novo Nordisk.

Because there are no warnings about NAION vision loss for Ozempic or Mounjaro in their current drug labels, those drug injury cases would only be filed against these responsible pharmaceutical companies — and not against patients’ doctors.

As regards the Mounjaro and Ozempic NAION vision loss lawsuits that are filed in federal courts, the U.S. Judicial Panel on Multidistrict Litigation (JPML) issued a December 2025 ruling that keeps these NAION lawsuits separate and apart from hundreds of earlier-filed Mounjaro and Ozempic cases involving gastrointestinal side effects.

The new federal court MDL case for the consolidation of Mounjaro and Ozempic NAION vision loss lawsuits is IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy [NAION] Products Liability Litigation, MDL No. 3163.

In addition to Mounjaro and Ozempic, this relatively new MDL No. 3163 lawsuits “consolidation” — which is not the same as a “class action”, but often confused with such — includes NAION cases involving a few other injectable GLP-1 agonist medicines from Eli Lilly (Zepbound) and Novo Nordisk (Wegovy and Rybelsus).

For these NAION vision loss lawsuits, we offer an online case evaluation service that is free and confidential, and without obligation:

Zepbound / Mounjaro Eye Side Effect NAION Case Evaluation Form

Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form

Experienced drug injury lawyer Tom Lamb will review your Case Evaluation Form, and he usually responds to you no later than the next business day.

If you would rather speak with Tom Lamb about your possible NAION eye side effect drug injury lawsuit, call him at 910-256-2971.

We look forward to assisting you or someone you know with a NAION case seeking legal compensation from the pharmaceutical drug company Eli Lilly (Mounjaro and Zepbound) or Novo Nordisk (Ozempic, Wegovy, and Rybelsus).

[Read the article in full at Drug Injury Watch]

Mounjaro / Zepbound

Free Case Evaluation

Strictly Confidential, No Obligation

Ozempic / Rybelsus / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

Ozempic Vision Loss Claims Compensation Payments Made in 2025

By

Some compensation payments for Ozempic vision loss claims are being made in Europe, according to recent news reports.

From this November 21, 2025, article, “Denmark Compensates Four Over Vision Loss Linked To Ozempic, Wegovy“, published by the Agence France Presse (AFP):

Four people in Denmark who developed serious eye conditions after using popular weight-loss and diabetes drugs Wegovy and Ozempic are entitled to compensation, an independent body ruled Friday.

More than 40 people had sought reimbursement after they said they had developed a serious eye condition as a result of using one of the drugs, both made by Novo Nordisk, according to the Danish Patient Compensation association.

The condition — NAION (non-arteritic anterior ischemic optic neuropathy) — is a lack of blood supply to the optic nerve, which can lead to a loss of vision.

The association said that it had ruled on five cases so far, and found four people who merited compensation….

In Denmark, health authorities generally pay out medical compensation for a drug injury such as NAION linked to Ozempic.  The Danish Patient Compensation association is an independent body that evaluates these types of patient claims on behalf of the government.

Over the past year, we have heard from people with Ozempic vision loss claims who are seeking compensation payments. In the US, those claims would be filed as drug injury lawsuits in the court system.  When successful, the resulting legal compensation payments would be made by the responsible drug company, Novo Nordisk.

Among the liability allegations that would be asserted in the lawsuits for those US Ozempic vision loss claims is Novo Nordisk’s failure to warn that semaglutide has been linked to an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) in several medical studies. The current Ozempic drug label in the US does not have any warnings about NAION.

We are investigating Ozempic vision loss claims for patients who have been diagnosed with NAION, as well as similar cases with the use of Wegovy or Rybelsus, which are two other semaglutide-containing drugs from Novo Nordisk.

Again, these drug injury lawsuits with vision loss claims involving Ozempic, Wegovy, and Rybelsus would be filed against Novo Nordisk for its failure to warn about the increased risk of NAION associated with semaglutide in its current US drug labels for those semaglutide-containing drugs.

If you are interested, you can submit an online Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form. Attorney Tom Lamb reviews each one of these submissions. He evaluates them as possible drug injury lawsuits seeking compensation payments for the person suffering from a loss of vision or blindness due to NAION. This case evaluation service is free and confidential, and without obligation.

[Read the article in full at Drug Injury Watch]

Ozempic / Rybelsus / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

Ozempic NAION Rate Higher in Recent 2025 Medical Study

By

It has been reported during the past couple of years that drugs with the active ingredient semaglutide, such as Ozempic, can increase the risk of non-arteritic anterior ischemic optic neuropathy (NAION). However, a new study presented this week at the 2025 annual meeting of the American Academy of Ophthalmology set the Ozempic NAION rate higher than we had seen previously.

From an October 20, 2025, News Release from the American Academy of Ophthalmology, “Do GLP-1 Drugs like Ozempic Cause or Prevent Vision Loss?“:

Researchers in an international collaboration across the University of Ottawa Eye Institute, University of Toronto, McMaster University, and Doheny Eye Institute UCLA conducted one of the largest global studies on the topic to date. Using data from the World Health Organization’s global database of drug safety reports, the authors analyzed data on 117,173 patients with diabetes taking semaglutide [Ozempic, as well as Rybelsus and Wegovy](GLP-1 drugs), empagliflozin, exenatide, tirzepatide, or insulin.

Results showed that people using GLP-1 drugs were 68.6 times more likely to develop NAION and eight times more likely to develop diabetic retinopathy than those taking empagliflozin, exenatide, insulin or metformin. The analysis found no significant association between tirzepatide (the active ingredient in other GLP-1 medications including Mounjaro and Zepbound) and NAION or diabetic retinopathy. [Emphasis added]

The American Academy of Ophthalmology (AAO) is the world’s largest association of eye physicians and surgeons.  So it makes this “Ozempic NAION rate higher” announcement significant.

The earlier Ozempic NAION rates, which were significantly lower, had already resulted in drug injury lawsuits being filed by patients against the responsible pharmaceutical company, Novo Nordisk.

Here is an April 2025 Drug Injury Watch article that you can read to learn more about lawsuits involving NAION, titled “Ozempic Vision Loss Lawsuits Have Been Filed by Patients Against Novo Nordisk“. That article lists some of the legal liability allegations regarding Novo Nordisk’s actions and failures. It also points out that the current Ozempic drug label does not warn about NAION as a possible eye side effect that can cause vision loss or blindness.

One wonders whether a medical study with the Ozempic NAION rate higher, as announced by this October 2025 AAO News Release, might increase the number of Ozempic vision loss lawsuits.

If you are interested in a possible Ozempic lawsuit seeking legal compensation for your NAION eye side effect, you can submit an Online Case Evaluation Form. It is free, confidential, and there is no obligation. We will reply to you no later than the next business day.

[Read the article in full at source]

Ozempic / Rybelsus / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

Ozempic and Mounjaro Increased Risk of NAION More Than Other Diabetes Drugs

By

A 2025 medical study considered whether treatment with either Ozempic (semaglutide) or Mounjaro (tirzepatide) is associated with an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) when compared to other antidiabetic medications. The researchers concluded that there is an Ozempic and Mounjaro increased risk of NAION.

A new medical article published in August 2025 had an important drug safety bottom-line statement: “In this study of patients with type 2 diabetes who had no prior eye disorders, patients prescribed [Ozempic (semaglutide)] or [Mounjaro (tirzepatide)] had an increased risk of NAION…”.

From the Discussion part of this recent medical journal article published August 11, 2025, online by JAMA Network Open, “Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes“:

In a population of patients with type 2 diabetes who had no prior diagnosis of eye diseases, this cohort study found that semaglutide [(Ozempic)] or tirzepatide [(Mounjaro)] compared with other antidiabetic medications was associated with a differential risk of optic nerve and visual pathways, including increased risk of NAION and other optic nerve disorders, but not optic neuritis, papilledema, optic atrophy, or optic disc orders. Cumulative incidence curves began to diverge immediately after medication initiation and continued to separate thereafter.

Related to this Ozempic and Mounjaro increased risk of NAION finding, we point out that there are additional drugs not used for diabetes but for obesity and weight loss purposes that contain semaglutide (Wegovy, Rybelsus) or tirzepatide (Zepbound). As we have covered in earlier articles, there is some evidence that the NAION eye-related side effect is associated with those additional drugs, too.

We will continue to follow the Ozempic and Mounjaro increased risk of NAION drug safety issue, as well as whether the two other semaglutide-containing drugs (Wegovy, Rybelsus) and the one other tirzepatide-containing drug (Zepbound) are associated with an increased risk of NAION.

[Read the article in full at source]

Mounjaro / Zepbound

Free Case Evaluation

Strictly Confidential, No Obligation

Ozempic / Rybelsus / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

Link Between Ozempic and NAION Also Involves the Eye Disorder AION

By

The European Medicines Agency (EMA) confirmed the link between Ozempic and NAION (non-arteritic anterior ischemic optic neuropathy) in early June 2025. This drug regulator went on to say a NAION warning would be added to the drug labels for the semaglutide-containing drugs Wegovy, Rybelsus, and Ozempic. Notably, but not surprisingly, the EMA did not mention the lesser-known eye disorder AION (anterior ischemic optic neuropathy) concerning the semaglutide drug label changes.

An excerpt from a Survey of Ophthalmology medical journal article explains the relationship between NAION and AION:

Anterior ischemic optic neuropathy (AION) results from ischemic damage to the anterior portion of the optic nerve, a region primarily supplied by the posterior ciliary artery circulation. Anterior ischemic optic neuropathy is divided into two types: arteritic AION (AAION), secondary to vasculitis (especially giant cell arteritis), and nonarteritic AION (NAION), secondary to non-inflammatory small vessel disease. NAION constitutes 95% of all AION and is the most common cause of acute optic neuropathy in people over the age of 50…. [Footnotes omitted.]

Given this relationship between NAION and AION, we should keep in mind that a person using Rybelsus, Wegovy, or Ozempic diagnosed with AION might have NAION as a side effect of their semaglutide-containing drug.

In turn, a person diagnosed with AION while using Ozempic, Wegovy, or Rybelsus could have a potential drug injury lawsuit to file against Novo Nordisk, the responsible pharmaceutical company, even though there was no specific mention of NAION by their eye doctor.

More information about these NAION lawsuits against the drug company is outlined in our prior article, “Ozempic Blindness Legal Cases Filed Against Novo Nordisk in April 2025“.

If you have been diagnosed with AION or NAION, we can assist you with a possible drug injury lawsuit that would be filed against Novo Nordisk, the responsible pharmaceutical company. To get started, you can complete our online Case Evaluation Form, or you can call attorney Tom Lamb (910-256-2971) to discuss your possible case.

[Read the article in full at source]

Ozempic / Rybelsus / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

Ozempic Blindness Legal Cases Filed Against Novo Nordisk in April 2025

By

Patients who have filed Ozempic blindness legal cases had developed nonarteritic anterior ischemic optic neuropathy (NAION) while using Ozempic. These cases are product liability failure to warn lawsuits filed against the responsible drug company, Novo Nordisk, because the Ozempic drug label does not warn about NAION as a possible eye side effect that can cause blindness.

Here are some of the allegations made in recently filed Ozempic blindness legal cases:

  • Despite available information, the drug company Novo Nordisk failed to warn patients about the risk of developing nonarteritic anterior ischemic optic neuropathy (NAION) when using Ozempic.
  • Novo Nordisk knew or should have known that there was reasonable evidence of a causal association between the use of Ozempic and NAION based on preclinical trials, premarket clinical trials, post-market surveillance, and adverse event reports about NAION being associated with Ozempic or other semaglutide drugs, such as Wegovy and Rybelsus.
  • A patient who suffered blindness due to NAION would not have used Ozempic — whether for type 2 diabetes treatment or as a weight-loss medication — if they had been provided a warning by Novo Nordisk about the risk of developing NAION when using Ozempic.

We have been investigating Ozempic blindness legal cases for almost a year now, starting soon after we published this article, “Wegovy, Rybelsus, and Ozempic Eye Side Effects: Semaglutide Linked to NAION“, on our Drug Injury Watch website back in early July 2024.

As indicated above, patients who have been diagnosed with semaglutide-related NAION and experienced blindness or vision loss may be entitled to legal compensation by filing a drug injury lawsuit against Novo Nordisk, the pharmaceutical company responsible for Ozempic, Wegovy, and Rybelsus.

Let us know if we can assist you or someone you know with an Ozempic blindness legal case involving NAION. Call (910) 256-2971 to speak directly to attorney Tom Lamb about a possible Ozempic drug injury lawsuit.

[Read the article in full at source]

Ozempic / Rybelsus / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

Vision Loss Linked to Ozempic and Rybelsus Use by Diabetes Patients

By

The relatively new drug safety issue of vision loss linked to Ozempic and Rybelsus was the subject of a recent medical study that had this stated Objective, or purpose: “To investigate the association between semaglutide use and the risk of NAION among patients with diabetes.”

On March 27, 2025, the JAMA Ophthalmology medical journal published this report, “Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy Risk Among Patients With Diabetes”, about that recent medical study. Of particular significance is that it presents new information about the time relationship between Ozempic and Rybelsus use dates by patients with type 2 diabetes and the diagnosis dates for their NAION. This can be found in the Results section of that March 2025 JAMA Ophthalmology article, at a part titled “Risk of NAION in Terms of Follow-Up Duration After Semaglutide Prescription”.

Given an apparent delay in the onset of vision loss linked to Ozempic and Rybelsus leading to a NAION diagnosis, it seems we may have a still-emerging drug injury lawsuit situation here. That is, the increasing use of Ozempic and Rybelsus in combination with this delay in vision loss leading to a NAION diagnosis means we might be just at the start of hearing from diabetes patients who have suffered this blinding eye-related side effect.

Drug injury lawsuits involving vision loss linked to Ozempic or Rybelsus filed for patients with a diagnosis of NAION (nonarteritic anterior ischemic optic neuropathy) would be against Novo Nordisk for its failure to warn about such vision loss. This is because the current drug labels for Ozempic and Rybelsus do not warn about any eye-related side effects, such as vision loss and blindness due to NAION.

We have been investigating possible drug injury lawsuits for patients who developed vision loss linked to Ozempic and Rybelsus, two of three semaglutide-containing drugs from Novo Nordisk. Their other semaglutide drug is Wegovy, approved by the FDA as a treatment for adult obesity and used for weight loss.

Let us know if we can assist you or someone else with an Ozempic, Rybelsus, or Wegovy drug injury case concerning nonarteritic anterior ischemic optic neuropathy (NAION) leading to vision loss.

[Read the article in full at source]

Ozempic / Rybelsus / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

Ozempic Eye Problems Caused by Semaglutide-Related NAION

By

Ozempic eye problems caused by semaglutide-related NAION are being investigated as possible drug injury lawsuits to be filed on behalf of patients against Novo Nordisk, the responsible drug company. Similar Wegovy eye problems and Rybelsus eye problems are also possible lawsuits against Novo Nordisk insofar that the active ingredient for those two drugs is semaglutide.

There are a couple of recent medical studies about semaglutide being associated with an increased risk of NAION that provide us with more information about Rybelsus, Wegovy, and Ozempic eye problems.

The first study was reported in the medical journal International Journal of Retina and Vitreous. It found that semaglutide was associated with a higher risk of NAION, having a 2.19 hazard ratio.

The second study, which is in preprint form and not yet published in a peer-reviewed journal (but was posted December 11, 2024, online at medRxiv) “…confirms that use of semaglutide is associated to an increased risk of NAION but also that the excess absolute risk is low.”

The Brigham and Women’s Hospital website provides some basic medical information about non-arteritic anterior ischemic optic neuropathy (NAION). People diagnosed with NAION often experience some degree of permanent vision impairment, which can be life-altering.

Our first article concerning Ozempic eye problems, “Ozempic Side Effects Include Eye Problems With Possible Vision Loss“, was posted in July 2024. Our second article was posted several months later, “Ozempic Linked to Vision Loss With Increased Risk of NAION Side Effect“.

We are investigating drug injury lawsuits seeking legal compensation for people who received a diagnosis of NAION (non-arteritic anterior ischemic optic neuropathy) while using one of Novo Nordisk’s semaglutide drugs, Ozempic, Wegovy, or Rybelsus.

[Read the article in full at source]

Ozempic / Rybelsus / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

Our Other Websites

DrugInjuryWatch.com

LambLawOffice.com

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971
TJL@LambLawOffice.com